Although we have witnessed a dramatic increase in the prevalence of antimicrobial resistance in respiratory pathogens over the past few years, resistance has infrequently been associated with clinical failures. However, as the prevalence and degree of resistance increases in the beta-lactams and the fluoroquinolones, newly approved for respiratory infections, failures are likely to occur.